… features of EGFR ins20 mutations and summarize recent data on emerging therapies for
patients with this subtype of EGFR-mutant non–small cell lung cancer (NSCLC). …

… EGFR‐tyrosine kinase inhibitor (TKI) combined with radiotherapy at metastatic sites in advanced
lung cancer harboring EGFR active mutations… local disease during EGFR‐TKI treatment. …

… of lung adenocarcinomas harbor a sensitizing EGFR mutation. Patients with EGFR-mutant
lung cancers have robust responses to EGFR tyrosine kinase inhibitors (EGFR-TKIs) but …

… of EGFR mutations in advanced lung adenocarcinoma can … than other mutations, while
an E21 mutation is expected to … for good prognosis in EGFR positive lung cancer, similar to …

… lung cancer (NSCLC). Whether these findings translate to epidermal growth factor receptor
(EGFR)–mutated … (TKI) therapy for EGFR-mutated synchronous oligometastatic NSCLC and …

… strategy for specific individuals carrying mutations associated with improved sensitivity to …
of only 6 EGFR mutation carriers in the validation set compared with 12 EGFR wild-type carriers…

… a database of 693 patients with NSCLC and uncommon EGFR mutations treated with
afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations. …

… illustrated that EGFR mutations are significantly … EGFR mutations and OS for these patients
[20,21,22,23,24,25,26,27,28,29]. Two studies have even suggested that EGFR mutations may …

… the prognostic impact of Exon 20ins were heterogeneous but highlighted poorer outcomes
in patients with Exon 20ins mutation compared with patients with other EGFR mutations and …

… We found 14 studies that used deep learning and CT imaging to predict EGFR mutation
status in patients with lung cancer. The largest dataset obtained so far included 914 patients in a …